Fluticasone furoate
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Intranasal |
ATC code | R01AD12 (WHO) R03BA09 (WHO) |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 0.51% (Intranasal) |
Protein binding | 91% |
Metabolism |
Intranasal Hepatic (CYP3A4-mediated) |
Biological half-life | 10 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | 80474-14-2 |
PubChem (CID) | 9854489 |
DrugBank | DB00588 |
ChemSpider | 8030195 |
UNII | JS86977WNV |
ChEBI | CHEBI:74899 |
ChEMBL | CHEMBL1676 |
ECHA InfoCard | 100.158.130 |
Chemical and physical data | |
Formula | C27H29F3O6S |
Molar mass | 538.576 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US), Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis administered by a nasal spray.[1]
The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.[2] As of 2015, it is also approved for the treatment of asthma. [3]
See also
References
- ↑ Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.
- ↑ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. May 10, 2013.
- ↑ "BREO® ELLIPTA® 100/25 (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)" (PDF).
This article is issued from Wikipedia - version of the 10/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.